Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150863 · ClinicalTrials.gov registry record · NA
Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT02150863: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT02150863 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02150863, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This project aims to treat field cancerization ( pre-skin cancers) in a manner that will reduce the future pre-skin cancers and non-melanoma skin cancers in patients with significant photodamage. This is 3 year prospective, randomized, controlled comparison of a single treatment with carbon dioxide laser resurfacing vs. carbon dioxide resurfacing plus autologous epidermal skin graft from a non sun exposed site vs. control. Thirty subjects will receive treatment with each of the modalities. The primary measures of efficacy are (a) count of the number of actinic keratosis and non melanoma skin cancers, (b) blinded evaluation of severity from standard digital photographs taken before and after the treatments, and (c) change in histology before and after treatment. Safety measures include (a) pain, (b) scarring, (c) wound healing, (d) and infection
Interventions
- DEVICE Ultrapulse Carbon Dioxide Laser
- DEVICE Cellutome epidermal harvesting system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02150863
The ClinicalTrials.gov registry entry for NCT02150863 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ultrapulse Carbon Dioxide Laser is the first listed.
NCT02150863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02150863 about?
NCT02150863 is a clinical study titled "Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study". This project aims to treat field cancerization ( pre-skin cancers) in a manner that will reduce the future pre-skin cancers and non-melanoma skin cancers in patients with significant photodamage. This is 3 year prospective, randomized, controlled comparison of a single treatment with carbon dioxide...
What is the current status of trial NCT02150863?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2014-08. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02150863?
The interventions under investigation include: Ultrapulse Carbon Dioxide Laser (DEVICE), Cellutome epidermal harvesting system (DEVICE).
Who is sponsoring clinical trial NCT02150863?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.